// Index Comparison
ACCE Biotech Catalysts vs ACCE Quality Compounders
Head-to-head: performance, risk profile, and constituent overlap between two ACCE indices.
US
ACCE Biotech Catalysts →
Binary catalyst pipeline — FDA approvals, late-stage trial readouts, and M&A targets. High conviction names with visible catalysts.
US
ACCE Quality Compounders →
High-ROIC, wide-moat businesses compounding shareholder value through pricing power, network effects, and recurring revenue.
ACCE Biotech Catalysts — risk
Volatility 30d+21.6%
Volatility 90d+25.2%
Sharpe 90d-1.05
Max drawdown-13.4%
Beta vs SPY0.91
ACCE Quality Compounders — risk
Volatility 30d+24.4%
Volatility 90d+23.5%
Sharpe 90d-2.08
Max drawdown-22.8%
Beta vs SPY0.56
Constituent overlap
0 stocks held by both indices (out of 6 and 6)
Top sectors — ACCE Biotech Catalysts
Healthcare100.0%
Top sectors — ACCE Quality Compounders
Technology35.4%
Financial Services29.9%
Consumer Defensive19.4%
Healthcare15.4%
ACCE Verdict
**ACCE Biotech Catalysts** has outperformed Quality Compounders since inception, losing 7.6% versus Quality Compounders' 13.67% decline, though both trail the benchmark's 4.74% gain. Biotech Catalysts shows marginally higher volatility at 25.2% but delivers a meaningfully better Sharpe ratio of -1.05 compared to Quality Compounders' brutal -2.08, while also limiting maximum drawdown to 13.4% versus Quality Compounders' painful 22.8% peak decline. These indices share virtually nothing beyond their current underperformance, with Biotech Catalysts targeting binary event-driven opportunities in drug development while Quality Compounders focuses on established businesses with sustainable competitive advantages.
**Biotech Catalysts emerges as the superior choice** for investors seeking high-conviction thematic exposure with defined risk parameters. Its higher beta of 0.91 versus Quality Compounders' 0.56 reflects the binary nature of FDA catalysts, but the significantly better risk-adjusted returns and smaller drawdowns demonstrate more disciplined position sizing. Quality Compounders appears to be suffering from multiple compression on expensive quality names, making it suitable only for investors with multi-year time horizons willing to endure substantial interim volatility for eventual mean reversion.